← Back to Clinical Trials
Recruiting NCT04691284

NCT04691284 Microbiome in Cancer Patients With High Dose Chemotherapy With Stem Cell Transplantation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04691284
Status Recruiting
Phase
Sponsor National Cancer Institute, Slovakia
Condition Hematologic Neoplasms
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2021-03-01
Primary Completion 2025-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Blood, urine and stool sampling

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2021-03-01 with a primary completion date of 2025-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Numerous in vitro and animal studies as well as growing number of clinical studies support the important role of microbiome in carcinogenesis and cancer treatment. Detection of changes in patients´ microbiome following hematopoietic cell transplantation/CAR-T cell therapy and correlations with adverse transplant outcomes, mainly infectious complications, acute and chronic GvHD, disease recurrence etc. could serve as predictive markers of immune recovery and treatment response.

Eligibility Criteria

Inclusion Criteria: * signed written informed consent * aged 18 years or older * patients planned to be treated by high-dose chemotherapy and hematopoietic cell transplantation or by CAR-T cell therapy in National Cancer Institute, Slovakia Exclusion Criteria: \- patients not-matching inclusion criteria

Contact & Investigator

Central Contact

Barbora Kašperová, MD

✉ barbora.kasperova@nou.sk

📞 +421-2-59378272

Principal Investigator

Luboš Drgoňa, Assoc. Prof.

STUDY CHAIR

National Cancer Institute, Slovakia

Frequently Asked Questions

Who can join the NCT04691284 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Hematologic Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04691284 currently recruiting?

Yes, NCT04691284 is actively recruiting participants. Contact the research team at barbora.kasperova@nou.sk for enrollment information.

Where is the NCT04691284 trial being conducted?

This trial is being conducted at Bratislava, Slovakia.

Who is sponsoring the NCT04691284 clinical trial?

NCT04691284 is sponsored by National Cancer Institute, Slovakia. The principal investigator is Luboš Drgoňa, Assoc. Prof. at National Cancer Institute, Slovakia. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology